8 papers in the library · 70 citations · publishing 2023-2026
PsyArXiv March 26, 2026 Broc A. Pagni, Stephen Ross, Sarah E. Mennenga et al. preprint
Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial
June 10, 2025 Gabrielle Agin-Liebes, Petros Petridis, Richard J. Zeifman et al. 1 citation preprint
A recent randomized, double-blind, placebo-controlled, parallel-group trial (NCT02061293) found that psilocybin-assisted therapy significantly improved drinking outcomes compared to an active placebo in adults with alcohol use disorder (AUD). In this secondary analysis, we assessed whether psilocybin-assisted therapy improved self-compassion and whether these changes predicted drinking...
Psychedelic Medicine November 25, 2024 Noah D Gold, Broc A. Pagni, Petros Petridis et al. 3 citations
Background: Psilocybin can produce long-term changes in personality, personal values, and behavior. Although psilocybin-assisted therapy (PAT) is being actively studied for various psychiatric conditions, its effects on personal values in patients with alcohol use disorder (AUD) remain unexplored. This study examined the effects of PAT on personal values in patients with AUD and assessed...
Nature Mental Health October 7, 2024 Petros Petridis, Jack Grinband, Gabrielle Agin-Liebes et al. 10 citations
Psilocybin-assisted psychotherapy (PAP) has shown promise in treating mood and anxiety disorders in patients with cancer. However, patients with cancer often suffer from more than just depression and anxiety, and so far, PAP's effect on other psychiatric symptoms remains largely unknown. To address this gap, we pooled previously unpublished data from two phase II, randomized, placebo-controlled...
Journal of Clinical and Translational Science April 1, 2024 Broc A. Pagni, Petros Petridis, Samantha K. Podrebarac et al. 1 citation
OBJECTIVES/GOALS: This pilot study investigated psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder (AUD). METHODS/STUDY POPULATION: Participants were recruited from a phase II, randomized, double-blind, placebo-controlled clinical trial investigating psilocybin-assisted therapy (PAT) for the treatment of AUD (NCT02061293). Eleven...
Scientific Reports February 7, 2024 Broc A. Pagni, Petros Petridis, Samantha K. Podrebarac et al. 30 citations
Abstract This pilot study investigated psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder (AUD). Participants were recruited from a phase II, randomized, double-blind, placebo-controlled clinical trial investigating psilocybin-assisted therapy (PAT) for the treatment of AUD (NCT02061293). Eleven adult patients completed task-based...
Journal of Psychopharmacology 2024 Lisa Bouchet, Zachary Sager, Antoine Yrondi et al. 22 citations
Background: Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and other substances. Data suggests that these compounds have the potential to treat mental health conditions that are especially prevalent in older adults such as depression, anxiety,...
Psychedelic medicine (New Rochelle, N.Y.) June 1, 2023 Noah D Gold, Samantha K. Podrebarac, Lindsay A White et al. 3 citations
More than 50 million people in the United States serve as uncompensated informal caregivers to chronically ill friends or family members. Providing care to a sick loved one can contribute to personal growth but can also cause significant strain. Caregiver distress refers to a constellation of physiological, psychological, interpersonal, and spiritual impairments that typically result when an...